Goldman’s 2026 Playbook: Ride Dividend Growth in Healthcare, Utilities, Industrials

Who Will Lead in 2026? Analysts Identify the Next Cohort of U.S. Growth Stocks
Published on: Oct 21, 2025

As global equity markets hover near record highs, Goldman Sachs is advising investors to start positioning for the next phase, highlighting sectors with robust and growing dividends as a potential safe harbor ahead of anticipated market swings.

In a recent report, the Wall Street giant projected that dividend growth for the S&P 500 will reach 6% in 2026, outpacing the broader market consensus of 5%. This forecast comes as the index has already demonstrated a 7% year-on-year increase in dividends per share for the first three quarters of 2024.

The analysis suggests that after a three-year bull run, a healthy market correction of 10-15% is widely anticipated. This environment, according to Goldman, presents an attractive opportunity for investors to rotate out of high-flying tech stocks and into quality companies with reliable payouts and the potential for significant dividend hikes in 2026.

“Dividend growth is typically a function of earnings growth in the current and prior two years,” the report noted, adding that futures markets appear pessimistic about future dividends, potentially creating a mispricing opportunity.

Goldman Sachs has pinpointed three key sectors—Healthcare, Utilities, and Industrials—as having superior dividend growth prospects. From its coverage, the firm has selected five stocks rated “Strong Buy” that offer compelling value at current levels.

Utilities

  • American Electric Power (AEP): One of the nation’s largest electric utilities, serving over five million customers across 11 states. It offers a reliable and attractive dividend with a 3.12% yield. Goldman Sachs set a $128 price target.
  • Eversource Energy (ES): This energy company serves customers in Connecticut, Massachusetts, and New Hampshire. It boasts an impressive track record of 23 consecutive years of dividend increases and provides a substantial 4.11% yield. The firm’s price target is $79.

Healthcare

  • Johnson & Johnson (JNJ): A diversified healthcare giant spanning pharmaceuticals, biotech, and medical devices. The stock trades at a modest forward P/E of 14.5 and carries a 2.81% dividend yield. Goldman views the current share price as highly attractive, with a $213 price target.
  • Merck & Co. (MRK): A global leader in developing and producing medicines, vaccines, and animal health products. Despite a share price decline of over 30% in the past year, its 3.61% dividend yield remains secure. Goldman’s price target is $93.

Industrials

  • L3Harris Technologies (LHX): A defense technology firm focused on providing integrated solutions across air, land, sea, space, and cyber domains. This industrial/defense stock offers shareholders a reliable 1.66% dividend yield. Goldman Sachs assigned a $327 price target.

As a leading global investment bank, Goldman Sachs’s research carries significant weight with institutional and high-net-worth investors. The report provides a clear roadmap for portfolio positioning, suggesting that a strategic shift into profitable, cash-rich industry leaders with a history of sustained dividend growth could offer stability amid potential volatility and position portfolios to capitalize on the expected dividend upswing in 2026.

Biotechnology Dividend Yielding Stocks Pharmaceutical Utilities